PurThread curtain may enhance hand hygiene efforts

On average it took only two days for control curtains to become contaminated with potentially pathogenic bacteria, while PurThread curtains withstood contamination an average of 14 days. This double-blinded Randomized Controlled Trial (RCT) is the first and only peer-reviewed study of its kind to assess the effectiveness of privacy curtains with antimicrobial properties in an active clinical setting.

The study titled, Novel Hospital Curtains with Antimicrobial Properties: A Randomized, Controlled Trial, was published online in the journal of Infection Control and Hospital Epidemiology.

Cleaner Patient Environment

"Without environmental hygiene, hand hygiene is insufficient to the challenge," said August Valenti, M.D infectious disease physician at InterMed Maine Medical Center.  "Healthcare Associated Infections (HAIs), are the fourth highest cause of mortality among US adults, and current hand hygiene efforts, while critical, are simply insufficient to the challenge of environmental contamination in the patient setting. This study suggests that continuously active surfaces, like those under development by PurThread, are solutions that may enhance hand hygiene efforts and provide an additional layer of patient safety."

Privacy curtains were chosen for the study because they are frequently touched by the freshly washed hands of healthcare workers before touching patients, and they often hang in place for weeks or months without being changed. 

A previous University of Iowa study, Hospital Privacy Curtains are Frequently and Rapidly Contaminated with Potentially Pathogenic Bacteria revealed 92% of hospital privacy curtains were contaminated with potentially dangerous bacteria such as MRSA (methicillin-resistant Staphylococcus aureus) and VRE within one week of being laundered.

Additionally, published studies have shown the transfer of bacteria from curtains to healthcare worker gloves, and that healthcare worker hands are considered leading vectors of pathogens to patients.

Ground–Breaking Study

"The study demonstrates PurThread's commitment to the highest standards of scientific rigour and clinical integrity as it develops this promising new technology," said Kathryn Bowsher, VP of Clinical and Regulatory Strategy at PurThread Technologies.

"The contamination variation, in this study, between PurThread experimental curtains and control curtains shows the antimicrobial materials being developed by PurThread can have a measurable and meaningful impact in a clinical setting.